Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
      Description

      The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.

      Conditions
      Thrombocytopenia, ImmuneHeparin Induced Thrombocytopenia
      Talk to us
      TERMINATED
      A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
      Description

      Compare Clinical Success and Costs in two Arms

      Conditions
      Suspected Heparin-Induced Thrombocytopenia
      Talk to us